|
1
|
Vogt A, Schmid S, Heinimann K, Frick H,
Herrmann C, Cerny T and Omlin A: Multiple primary tumours:
Challenges and approaches, a review. ESMO Open.
2(e000172)2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Altekruse SF, Kosary CL, Krapcho M, Neyman
N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H
(eds), et al: SEER Cancer Statistics Review, 1975-2007. National
Cancer Institute, Bethesda, MD, 2010. Available from: http://seer.cancer.gov/csr/1975_2007.
|
|
3
|
Leone G, Pagano L, Ben-Yehuda D and Voso
MT: Therapy-related leukemia and myelodysplasia: Susceptibility and
incidence. Haematologica. 92:1389–1398. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau
JYN, Wang JC and Liu LF: Roles of DNA topoisomerase II isozymes in
chemotherapy and secondary malignancies. Proc Natl Acad Sci USA.
104:11014–11019. 2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Allen PJ, Kuk D, Castillo CF, Basturk O,
Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide
V, He J, et al: Multi-institutional validation study of the
American joint commission on cancer (8th edition) changes for T and
N staging in patients with pancreatic adenocarcinoma. Ann Surg.
265:185–191. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kang MJ, Jang JY, Chang YR, Kwon W, Jung W
and Kim SW: Revisiting the concept of lymph node metastases of
pancreatic head cancer: Number of metastatic lymph nodes and lymph
node ratio according to N stage. Ann Surg Oncol. 21:1545–1551.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ghiorzo P, Ciotti P, Mantelli M, Heouaine
A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris
A, et al: Characterization of ligurian melanoma families and risk
of occurrence of other neoplasia. Int J Cancer. 83:441–448.
1999.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bergman W, Watson P, de Jong J, Lynch HT
and Fusaro RM: Systemic cancer and the FAMMM syndrome. Br J Cancer.
61:932–936. 1990.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tucker MA, Fraser MC, Goldstein AM, Elder
DE, Guerry D IV and Organic SM: Risk of melanoma and other cancers
in melanoma-prone families. J Invest Dermatol. 100:350S–355S.
1993.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Goldstein AM, Fraser MC, Struewing JP,
Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM,
Dracopoli NC, Clark WH Jr, et al: Increased risk of pancreatic
cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J
Med. 333:970–974. 1995.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Swerdlow AJ, Storm HH and Sasieni PD:
Risks of second primary malignancy in patients with cutaneous and
ocular melanoma in Denmark, 1943-1989. Int J Cancer. 61:773–779.
1995.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bergman W, Palan A and Went LN: Clinical
and genetic studies in six Dutch kindreds with the dysplastic
naevus syndrome. Ann Hum Genet. 50:249–258. 1986.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gabree M, Patel D and Rodgers L: Clinical
applications of melanoma genetics. Curr Treat Options Oncol.
15:336–350. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Goldstein AM, Chan M, Harland M,
Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G,
Bishop DT, Bressac-de Paillerets B, et al: High-risk melanoma
susceptibility genes and pancreatic cancer, neural system tumors,
and uveal melanoma across GenoMEL. Cancer Res. 66:9818–9828.
2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Goldstein AM, Chan M, Harland M, Hayward
NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G,
Bruno W, et al: Features associated with germline CDKN2A mutations:
A GenoMEL study of melanoma-prone families from three continents. J
Med Genet. 44:99–106. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lynch HT, Fusaro RM, Pester J, Oosterhuis
JA, Went LN, Rumke P, Neering H and Lynch JF: Tumour spectrum in
the FAMMM syndrome. Br J Cancer. 44:553–560. 1981.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fusaro RM, Lynch HT, Lynch JF and Madsen
NJ: Phenotypic variation and systemic cancer in the FAMMM syndrome.
Pigment Cell Res. 1:152–157. 1988.
|
|
18
|
Leachman SA, Lucero OM, Sampson JE,
Cassidy P, Bruno W, Queirolo P and Ghiorzo P: Identification,
genetic testing, and management of hereditary melanoma. Cancer
Metastasis Rev. 36:77–90. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Whelan AJ, Bartsch D and Goodfellow PJ:
Brief report: A familial syndrome of pancreatic cancer and melanoma
with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med.
333:975–977. 1995.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Caldas C, Hahn SA, da Costa LT, Redston
MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern
SE: Frequent somatic mutations and homozygous deletions of the p16
(MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 8:27–32.
1994.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Serrano M, Hannon GJ and Beach D: A new
regulatory motif in cell-cycle control causing specific inhibition
of cyclin D/CDK4. Nature. 366:704–707. 1993.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Gruis NA, van der Velden PA, Sandkuijl LA,
Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W and Frants RR:
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial
melanoma kindreds. Nat Genet. 10:351–353. 1995.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bishop DT, Demenais F, Goldstein AM,
Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo
P, Gruis N, Hansson J, et al: Geographical variation in the
penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst.
94:894–903. 2002.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vasen HF, Gruis NA, Frants RR, van Der
Velden PA, Hille ET and Bergman W: Risk of developing pancreatic
cancer in families with familial atypical multiple mole melanoma
associated with a specific 19 deletion of p16 (p16-Leiden). Int J
Cancer. 87:809–811. 2000.PubMed/NCBI
|
|
25
|
de Snoo FA, Bishop DT, Bergman W, van
Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ,
Vasen HF, ter Huurne JA, Frants RR, et al: Increased risk of cancer
other than melanoma in CDKN2A founder mutation
(p16-Leiden)-positive melanoma families. Clin Cancer Res.
14:7151–7157. 2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vasen H, Ibrahim I, Ponce CG, Slater EP,
Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, et
al: Benefit of surveillance for pancreatic cancer in high-risk
individuals: Outcome of long-term prospective follow-up studies
from three European expert centers. J Clin Oncol. 34:2010–2019.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Bergman W and Gruis N: Familial melanoma
and pancreatic cancer. N Engl J Med. 334:471–472. 1996.PubMed/NCBI
|
|
28
|
van der Velden PA, Sandkuijl LA, Bergman
W, Pavel S, van Mourik L, Frants RR and Gruis NA: Melanocortin-1
receptor variant R151C modifies melanoma risk in Dutch families
with melanoma. Am J Hum Genet. 69:774–779. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Demenais F, Mohamdi H, Chaudru V,
Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK,
Gillanders E, Elder DE, et al: Association of MC1R variants and
host phenotypes with melanoma risk in CDKN2A mutation carriers: A
GenoMEL study. J Natl Cancer Inst. 102:1568–1583. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fang J, Jia J, Makowski M, Xu M, Wang Z,
Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, et al: Functional
characterization of a multi-cancer risk locus on chr5p15.33 reveals
regulation of TERT by ZNF148. Nat Commun. 8(15034)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Rachakonda S, Kong H, Srinivas N,
Garcia-Casado Z, Requena C, Fallah M, Heidenreich B, Planelles D,
Traves V, Schadendorf D, et al: Telomere length, telomerase reverse
transcriptase promoter mutations, and melanoma risk. Genes
Chromosomes Cancer. 57:564–572. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Fortes C, Mastroeni S, Melchi F, Anzidei
P, Innocenzi L, Giovinazzo R, Antonelli G, Pasquini P and
Venanzetti F: P5 polymorphisms in GSTM1, GSTT1, coffee consumption
and cutaneous melanoma risk. Melanoma Res. 20:e45–e46. 2010.
|
|
33
|
Randerson-Moor JA, Taylor JC, Elliott F,
Chang YM, Beswick S, Kukalizch K, Affleck P, Leake S, Haynes S,
Karpavicius B, et al: Vitamin D receptor gene polymorphisms, serum
25-hydroxyvitamin D levels, and melanoma: UK case-control
comparisons and a meta-analysis of published VDR data. Eur J
Cancer. 45:3271–3281. 2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hille ET, van Duijn E, Gruis NA, Rosendaal
FR, Bergman W and Vandenbroucke JP: Excess cancer mortality in six
Dutch pedigrees with the familial atypical multiple mole-melanoma
syndrome from 1830 to 1994. J Invest Dermatol. 110:788–792.
1998.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lynch HT, Smyrk T, Kern SE, Hruban RH,
Lightdale CJ, Lemon SJ, Lynch JF, Fusaro LR, Fusaro RM and
Ghadirian P: Familial pancreatic cancer: A review. Semin Oncol.
23:251–275. 1996.PubMed/NCBI
|
|
37
|
Brentnall TA, Bronner MP, Byrd DR, Haggitt
RC and Kimmey MB: Early diagnosis and treatment of pancreatic
dysplasia in patients with a family history of pancreatic cancer.
Ann Intern Med. 131:247–255. 1999.PubMed/NCBI View Article : Google Scholar
|
